Immune to Cancer: The CRI Blog
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
Longboarding in the Fight Against Cancer with James McGary
Professional longboarder James is going the distance: he's longboarding from Seattle to New York City to raise…
-
Pam G’s Immunotherapy Story
Lung Cancer | Diagnosed 2013 I would not be alive today if it were not for this… -
CRI Scientists Honored With Five AACR Awards
Carl June, Elizabeth Jaffee, James Allison, David Baltimore, and Owen Witte pick up prestigious cancer awards.
-
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
CRI’s James Allison, Arming the Immune System
The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
-
Across the CEO’s Desk: February 2015 Roundup
CRI's CEO Jill O'Donnell-Tormey, PhD, shares some of the latest news in cancer immunotherapy.
-
CRI’s Impact on Colorectal Cancer Immunotherapy
CRI scientists have contributed significantly to the immunological understanding and treatment of colorectal cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.